This study aimed to develop mapping algorithms from the Expanded Prostate Cancer Index Composite (EPIC) and the Short-Form (SF) Health Surveys to the Patient-Oriented Prostate Utility Scale (PORPUS), an econometric instrument specifically developed for patients with prostate cancer.
Since 2004, multiple blockbuster drugs have been approved for men with metastatic prostate cancer. Nevertheless, it has been reported that no improvement in survival was observed between 2004 and 2009.
Biochemical recurrence is an evolving space in prostate cancer, with increasing multidisciplinary involvement. Androgen deprivation therapy has shown proof of its value in complementing salvage radiotherapy in high-risk biochemical relapsing patients; ongoing trials aim to further refine this treatment combination.
The International Classification of Diseases-10-Procedure Coding System (ICD-10-PCS) is markedly more complex than the preceding ICD-9 system, which has increased the difficulty of identifying radical cystectomy (RC) in administrative datasets.
To compare perioperative and oncologic outcomes of intracorporeal (ICNB) and extracorporeal neobladder (ECNB) following robot assisted radical cystectomy (RARC) from a multi-institutional, prospectively maintained database, the International Robotic Cystectomy Consortium (IRCC).
There has been a recent emergence of novel minimally invasive surgical therapies (MIST) for the treatment of benign prostatic hyperplasia (BPH). Prostatic urethral lift (PUL, Urolift) and transurethral water vapor therapy (TWVT, Rezum) are performed in the ambulatory setting and offer superior preservation of sexual function and less risk of retrograde ejaculation. Aquablation offers short […]
(UroToday.com) In a session at the American Society for Radiation Oncology (ASTRO) Annual Congress focused on the care of patients with intermediate and high-risk prostate cancer, Dr. Zapatero presented 10-year results of a phase III randomized trial of high-dose radiotherapy and risk-adapted androgen deprivation therapy in localized prostate cancer. This study, with 5-year results initially presented at […]
(UroToday.com) The 2021 American Society for Radiation Oncology (ASTRO) Hybrid Annual Meeting’s included a session on biomarkers and salvage radiotherapy and discussion by Dr. David J. Konieczkowski regarding the impact of AR-V7 and other androgen receptor splice variant expression on outcomes of post-prostatectomy salvage therapy.
(UroToday.com) The 2021 American Society for Radiation Oncology (ASTRO) Hybrid Annual Meeting included a presentation by Dr. Robert Dess discussing the prognostic and predictive performance of routine clinicopathologic variables in men enrolled in phase III randomized clinical trials in localized prostate cancer.
(UroToday.com) The 2021 American Society for Radiation Oncology (ASTRO) Hybrid Annual Meeting included a presentation by Dr. Amar Kishan discussing the impact of high dose radiotherapy in localized prostate cancer based on an individual patient data meta-analysis of 15 randomized trials.
